Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Ahead of World Diabetes Day on November 14, the Bangkok Ride & Run 2024 brought together hundreds in support of diabetes ...

The global diabetes crisis is worsening. With over 537 million people currently living with diabetes worldwide, the ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Both injections are produced by the Denmark-headquartered drugmaker Novo Nordisk. The shots are different forms of the drug semaglutide. The Food and Drug Administration (FDA) said that it is ...

We're days away from what could be a historic election, in a highly unusual campaign season. America could get its first ...

Healthcare is possibly the most overlooked of all the mega-trends. But this may leave investors with more opportunities once ...

In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...